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Abstract
Background:  People with non-diabetic hyperglycaemia might be at risk of lacking adequate
control for cardiovascular risk factors. Our aim was to determine the extent of health care
utilization and provision in primary care and to evaluate the risk of cardiovascular disease in
persons with an elevated risk score in a stepwise diabetes screening programme.
Methods: A total of 56,978 non-diabetic patients, aged 50–70 years, from 79 practices in the
Netherlands were invited to participate in a screening programme starting with a questionnaire.
Those with an elevated score, underwent further glucose testing. Screened participants with type
2 diabetes (n = 64), impaired glucose tolerance (IGT) (n = 62), impaired fasting glucose (IFG) (n =
86), and normal glucose tolerance (NGT) (n = 142) were compared after three years regarding use
of medication, care provider encounters and occurrence of CVD.
Results:  In all glucose regulation categories cardiovascular medication was prescribed more
frequently during follow-up with the strongest increase in diabetic patients. Number of practice
visits was higher in diabetic patients compared to those in the other categories. Glucose, lipids, and
blood pressure were measured most frequently in diabetic patients. Numbers of cardiovascular
events in participants with NGT, IFG, IGT and diabetes were 16.7, 32.6, 17.3 and 15.7 per 1,000
person-years (non significant), respectively.
Conclusion: After three years of follow-up, screened non-diabetic participants with an elevated
risk score had cardiovascular event rates comparable with diabetic patients. Screened non-diabetic
persons are at risk of lacking optimal control for cardiovascular risk factors while screen-detected
diabetic patients were controlled adequately.
Background
Type 2 diabetes is an important health problem and the
costs associated with its treatment are increasing [1]. Dia-
betes is a significant cause of cardiovascular morbidity
and mortality. In addition, patients with 'pre-diabetes'
(impaired fasting glucose (IFG) and impaired glucose tol-
erance (IGT)) are at an increased risk for cardiovascular
diseases (CVD) and higher medical care costs [2,3].
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Awareness of the cardiovascular risk of impaired glucose
regulation among general practitioners is relatively low
[4]. As a result people with non-diabetic hyperglycaemia
might be at risk of lacking adequate control for their car-
diovascular risk factors. Participants in a diabetes screen-
ing programme who had an elevated score on a risk
questionnaire already had a high mortality risk whether or
not subsequent diagnostic testing classified them to have
diabetes [5,6]. This suggests that it may be of greater ben-
efit to intervene in the larger population with an increased
cardiovascular risk rather than only in the smaller group
of screen-detected people with diabetes.
Screening for diabetes is recommended by the American
Diabetes Association, although definitive evidence of its
effectiveness is lacking [7,8]. Diabetic patients identified
in a screening programme typically receive treatment to
control cardiovascular risk factors while people in whom
the diagnosis of diabetes could not be established are usu-
ally reassured. However, little is known about the natural
history of screened people with an elevated risk score in a
diabetes screening programme. Therefore, it is disputable
whether reassurance is justified.
The aim of the present study was to determine the use of
medication and the frequency of care provider encounters
after three years of follow-up of diabetic and non-diabetic
persons with an elevated risk score in a population-based
screening programme. In addition, we evaluated their risk
of CVD during three years of follow-up.
Methods
This study is part of the ADDITION study (Anglo-Danish-
Dutch Study of Intensive Treatment in People with
Screen-Detected Diabetes in Primary Care), a randomised
controlled trial consisting of a screening and an interven-
tion study [9]. Screen-detected diabetic patients in prac-
tices in the intervention arm of the ADDITION study
undergo a multifactorial treatment according to strict tar-
gets to reduce their cardiovascular risk. Those in the con-
trol practices receive routine care according to the
guidelines from the Dutch College of General Practition-
ers [10]. The study was approved by the medical-ethical
committee of the University Medical Center Utrecht. Par-
ticipants gave written informed consent.
In the Netherlands, we performed a population-based
screening for type 2 diabetes from May 2002 to April 2004
[11]. The screening algorithm in the three countries was
comparable [12]. In the Netherlands, the screening started
with a self-completed questionnaire, mailed to 56,978
non-diabetic, predominantly Caucasian, registered
patients, aged 50–70 years, from 79 general practices in
the southwestern region of the Netherlands. This vali-
dated questionnaire contained questions about age, gen-
der, body mass index, family history of diabetes, frequent
thirst, use of antihypertensive medication, shortness of
breath, claudication, and cycling [13].
Participants were invited for further diagnostic testing
including the OGTT if they scored above threshold on the
questionnaire [11]. All subjects were classified as having
either type 2 diabetes, IGT, IFG or normal glucose toler-
ance (NGT) according to the 1999 WHO criteria [14].
Diagnosis of diabetes was based on two diabetic glucose
values [11]. Eventually, we detected 586 new diabetic
patients. A letter with the test results was handed over to
all participants and the implications were discussed. In
addition, participants' general practitioners were
informed.
Study population
For the present study, all participants with a risk score
above threshold from 24 practices, screened from May to
October 2002, were eligible. Screen-detected diabetic
patients from practices in the intervention arm of the
ADDITION study were excluded. Finally, 392 participants
were included: all 70 diabetic patients in the control arm
of the study, all 66 persons with IGT, all 96 persons with
IFG and 160 people with normal glucose tolerance
(NGT), randomly selected out of all 3,258 participants
with NGT.
Of these people, 38 were not found in the patient files in
the practices, partially because of changing of practice or
address since screening, partially for reasons unknown.
Thus, we collected data at baseline and after three years
from 354 participants in four categories of glucose regula-
tion: participants with type 2 diabetes receiving usual care
(n = 64), with IGT (n = 62), with IFG (n = 86), and with
NGT (n = 142).
Measurements
Baseline and follow-up data were collected by one of the
authors (MA) from the medical records of the patients in
the practices. All practices gave approval of investigation
of their patients' medical records. Incidence of diabetes,
all cause mortality and cardiovascular morbidity (non-
fatal myocardial infarction, non-fatal stroke, amputation,
hospitalisation for angina pectoris, hospitalisation for
congestive heart failure, coronary revascularisation,
peripheral vascular events) were recorded with date of
diagnoses. Numbers of care provider encounters, referrals
to a medical specialist (cardiologist, internist, neurolo-
gist), and glucose, lipids and blood pressure measure-
ments during follow-up, were derived from patients'
medical records. Use of medication (lipid lowering drugs,
antihypertensive agents, acetylsalicylic acid) was assessed
at baseline and after three years (issued data). Values of
anthropometric (BMI and blood pressure) and biochemi-BMC Family Practice 2008, 9:67 http://www.biomedcentral.com/1471-2296/9/67
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cal (glucose, cholesterol, HDL-cholesterol, LDL-choles-
terol, and triglycerides) characteristics, derived from the
patient records, were determined at baseline and after
three years. All practices collaborate with the same
regional laboratory (SHL Center for Diagnostic Support in
Primary Care, Etten-Leur, The Netherlands) for all bio-
chemical tests.
Statistical analyses
Data were analyzed applying the SPSS statistical package
(version 11.0). Gender and age at baseline were compared
between the different diagnostic categories using the χ2
test for dichotomous variables and ANOVA for continue
variables, respectively. Cumulative occurrence of diabetes
in the non-diabetic categories during follow-up was com-
pared using the χ2 test. Health care encounters were ana-
lyzed using the Mann-Whitney test. Differences in use of
medication were examined with the χ2 test. Paired-sam-
ples t-tests were used to compare baseline with follow-up
antropometric and biochemical measurements within
each diagnostic category. Cardiovascular events and death
were calculated per diagnostic category per 1,000 person-
years of follow-up. Cox regression analysis with age and
gender entered as covariates in the model was used to
examine whether the diagnostic categories have different
risks regarding mortality and cardiovascular morbidity. A
P value < 0.05 was considered significant.
Results
Characteristics of participants in the different diagnostic
categories are presented in Table 1. A total of 24 subjects
(8.2%) in the non-diabetic categories developed diabetes.
Development of diabetes was highest among participants
with IGT (16.1%).
Use of medication at baseline and after three years is
shown in Table 2. At baseline, use of cardiovascular med-
ication in all diagnostic categories was comparable. Over-
all, in all diagnostic categories an increase in use of
medication was found. Both the increase in use of lipid
lowering drugs and antihypertensive agents were strongest
in participants with diabetes (35.9% and 42.2%, respec-
tively). In addition, Table 2 shows a significant decrease in
blood pressure in the follow-up period in all categories
except in persons with NGT. Furthermore, we found in
type 2 diabetic patients a significant improvement in lev-
els of total cholesterol and LDL-cholesterol (total choles-
terol (mean ± SD) 5.6 ± 1.2 mmol/l (at baseline) and 4.7
± 1.0 mmol/l (after one year); LDL-cholesterol 3.6 ± 1.0
mmol/l and 2.9 ± 0.8 mmol/l, respectively). HDL-choles-
terol and triglycerides also improved but not significantly:
HDL-cholesterol changed from 1.0 ± 0.3 mmol/l at base-
line to 1.1 ± 0.3 mmol/l and triglycerides from 2.4 ± 2.5
mmol/l to 1.6 ± 0.8 mmol/l. BMI in diabetic patients
decreased from 31.0 ± 5.2 kg/m2 to 29.1 ± 5.2 kg/m2. In
the non-diabetic categories, we did not find enough meas-
urements of lipids and weight in the patient records,
which made a comparison with the type 2 diabetes cate-
gory impossible.
During follow-up diabetic patients contacted significantly
more often the practice (median 33.5, interquartile range
22.3–46.0) (Table 3). Frequencies of blood pressure, glu-
cose and lipids measurements were highest in type 2 dia-
betic patients. Persons with IGT scored higher in this
respect than people with IFG and NGT. The numbers of
referrals to a the cardiologist, internist and neurologist did
not differ between the different diagnostic categories.
Numbers of cardiovascular events and death in partici-
pants with NGT, IFG, IGT and diabetes were 16.7, 32.6,
17.3 and 15.7 per 1,000 person-years, respectively. Age
and gender adjusted differences between the diagnostic
categories were not statistically significant (Table 4).
Discussion
In this study we followed people in different glucose reg-
ulation categories during three years, who all had an ele-
vated risk score in a diabetes screening programme. In the
follow-up period almost one in six participants with IGT
developed diabetes, whereas almost one in ten people
with IFG did. In all glucose regulation categories cardio-
vascular medication was prescribed more frequently at
end of follow-up compared to baseline with the strongest
increase in diabetic patients. Numbers of practice visits
and cardiovascular risk factors measurements were high-
est in diabetic participants followed by those with IGT.
Apparently, people with diabetes were treated more inten-
Table 1: Characteristics of participants in different categories of glucose regulation
NGT
(n = 142)
IFG
(n = 86)
IGT
(n = 62)
type 2 diabetes
(n = 64)
Age (years) (at baseline) 61.5 ± 5.9 61.0± 5.4 61.7 ± 5.8 61.0 ± 5.4
Gender (male %) 39.4* 53.5 48.4 60.9
Incidence of diabetes n (%) 6 (4.2)† 8 (9.3) 10 (16.1) -
Data are presented as mean ± SD except where otherwise specified.
* NGT significantly different from IFG and type 2 diabetes; † NGT significantly different from IFG and IGT.BMC Family Practice 2008, 9:67 http://www.biomedcentral.com/1471-2296/9/67
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sively and down to target, compared to high risk non-dia-
betic individuals, who are eligible for preventive measures
as well. Our findings indicate that there is a missed oppor-
tunity for effective preventive care for non-diabetic high
risk individuals in general practice. Screened non-diabetic
persons with an elevated risk score appeared to have sub-
sequent cardiovascular events at a level comparable with
diabetic patients.
Most other studies also showed the progression rate to
type 2 diabetes to be higher in people with IGT than in
those with IFG with the highest rate in people with both
IGT and IFG (combined-IGT) [15-18]. The incidence rate
of diabetes in persons with IGT and IFG in our study is
rather low compared with findings in other studies. The
progression rate in the ADDITION Denmark study was
higher. Participants with IGT and IFG in this study were
invited for re-examination after one year and diagnosis of
diabetes was based on one diabetic glucose value [12]. In
our study diabetes was diagnosed during regular practice
visits which may be less sensitive. In the Dutch Hoorn
study, the cumulative incidence of diabetes was 64.5%
[16]. However, these were participants with combined-
IGT, the mean follow-up was 5.8–6.5 years and partici-
pants were aged 50 to 75 years at baseline.
Although IGT is more strongly associated with cardiovas-
cular disease than IFG [19-22], in this study most cardio-
vascular events occurred in participants with IFG and least
in diabetic patients. However, differences between the
four diagnostic categories were not statistically significant.
It may be assumed that the relatively low event rate in dia-
betic patients is associated with the provision of struc-
tured diabetes care following the diagnosis of diabetes,
while participants in the other diagnostic categories were
lacking such care. That said, non-diabetic persons are
being controlled for hypertension and dyslipidaemia
according to Dutch national guidelines, but this is done
less systemically than in those with diabetes. Prevention
or delay of onset of type 2 diabetes is possible in individ-
uals with IGT, either by lifestyle changes or by pharmaco-
logical interventions [23,24]. However, awareness of the
clinical significance of IGT among general practitioners is
relatively low [4]. General practitioners need to be moti-
vated and resourced to perform preventive strategies [25].
These findings seem consistent with our observation that
Table 2: Characteristics in different categories of glucose regulation at baseline and after three years
NGT (n = 142) IFG (n = 86) IGT (n = 62) type 2 diabetes (n = 64)
T0 T3 T0 T3 T0 T3 T0 T3
Use of medication
Antihypertensive drugs (%) 21.1 42.3 31.4 48.8 41.9 66.1 31.3 67.2*
Lipid lowering drugs (%) 14.8 32.4 17.4 27.9 14.5 32.3 14.1 56.3†
Acetylsalicylic acid (%) 9.2 19.7 16.3 22.1 11.3 22.6 9.4 15.6
Anthropometric characteristics
SBP (mm Hg) 147 ± 33 146 ± 20 151 ± 24 145 ± 23‡ 160 ± 24 143 ± 21‡ 156 ± 21 140 ± 13‡
DBP (mm Hg) 83 ± 20 84 ± 10 86 ± 11 82 ± 10‡ 89 ± 12 80 ± 11‡ 89 ± 9 80 ± 7‡
Data are presented as mean (± SD) except where otherwise specified.
T0, at baseline; T3, after three years; SBP, systolic blood pressure; DBP, diastolic blood pressure.
* Difference in use of medication at T3 and T0 in type 2 diabetes category significantly different from differences in NGT and IFG categories; † 
difference in use of medication at T3 and T0 in type 2 diabetes category significantly different from differences in all other categories; ‡ difference in 
mean in diagnostic category at T0 and T3 significant.
Table 3: Health care encounters in different categories of glucose regulation over three years
NGT
(n = 142)
IFG
(n = 86)
IGT
(n = 62)
type 2 diabetes
(n = 64)
Care provider encounters 20.0 (11.0–34.0) 23.0 (9.0–34.0) 26.0 (15.0–43.5)* 33.5 (22.3–46.0)†
Blood pressure measurements 2.0 (0–5.0) 2.0 (0–5.0) 4.0 (1.0–6.0)* 5.0 (3.0–7.0)†
Glucose measurements 1.0 (0–2.0) 1.0 (0–3.0) 2.0 (1.0–4.0)* 13.0 (7.3–14.8)†
Lipid measurements 0.5 (0–2.0) 1.0 (0–2.0) 1.0 (0–2.0)‡ 3.0 (2.0–4.0)†
Referrals to specialist 2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (0–3.0)
Data are presented as median (interquartile range).
* IGT significantly different from all other categories; † type 2 diabetes significantly different from all other categories; ‡ IGT significantly different 
from NGT and type 2 diabetes.BMC Family Practice 2008, 9:67 http://www.biomedcentral.com/1471-2296/9/67
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diabetic patients contacted the practice more frequently
compared with non-diabetic participants. In addition, it is
understandable that the increase in use of cardiovascular
medication after three years was highest in diabetic
patients. In the non-diabetic categories the use of cardio-
vascular medication also increased, although this increase
was considerably less. We should realise that all partici-
pants had an elevated risk score indicating an unfavoura-
ble cardiovascular risk profile. The 1999 guidelines from
the Dutch College of General Practitioners recommended
yearly glucose testing in people with increased (but non-
diabetic) fasting glucose levels. However, it is not solely
an issue to test people with impaired glucose regulation
for diabetes. It seems more appropriate to control them
for cardiovascular risk factors.
Some limitations of this study need to be addressed.
Firstly, screen-detected diabetic patients who were treated
intensively in the intervention arm of the ADDITION
study were excluded. Care providers in these practices
might have developed during the study an increased 'dia-
betes awareness' possibly resulting in a changed attitude
towards people with IFG or IGT. However, the number of
health care encounters of non-diabetic participants in
intervention and control practices did not differ signifi-
cantly (data not shown). Secondly, we could not compare
plasma lipids between the different diagnostic categories
simply because of not finding enough data of the non-dia-
betic participants in their records. Nevertheless, it is
unlikely that the plasma lipid levels in the non-diabetic
participants have improved to the same extent as in the
diabetic patients, since the increase in use of lipid lower-
ing drugs during follow-up was substantially lower in par-
ticipants without diabetes. Thirdly, this sub-study of the
ADDITION study was not designed prospectively to inves-
tigate differences in the occurrence of cardiovascular
events between the glucose regulation categories. No
power analysis was performed. The relatively small size of
the diagnostic categories may account for the non-signifi-
cant differences between the groups. The small sample
size combined with low event rate might have lead to type
2 errors. Therefore, it is not allowed to draw firm conclu-
sions regarding the non-significance of the CVD risk
between the groups. Despite this, we feel that the occur-
rence of CVD is consistent with the trend in our other
observations. Still, our purpose primarily was to examine
whether high risk non-diabetic participants receive ade-
quate control for CVD risk factors after the screening.
Fourthly, data collection was not done blinded. However,
it may be assumed that this did not introduce bias because
data were derived retrospectively from patients' files at the
practices and in all practices record-keeping of the patients
was computerized.
Our data indicate that screened non-diabetic people with
an elevated score on a questionnaire, mainly consisting of
cardiovascular items, who do not receive structured care
following the screening should not be reassured only
because of not having diabetes. People diagnosed with
diabetes in a screening programme seem better off regard-
ing their CVD risk than those in whom diagnosis of dia-
betes could not be established.
Conclusion
The diabetes risk questionnaire identified people with
increased cardiovascular risk. Screened participants with
an elevated risk score but without diabetes are at risk of
lacking optimal medical care in order to control for cardi-
Table 4: Cardiovascular events and death from all causes in different categories of glucose regulation
NGT
(n = 142)
IFG
(n = 86)
IGT
(n = 62)
type 2 diabetes
(n = 64)
Person-years of follow-up 420.4 245.4 173.5 191.5
Event n per 1000 person-
years
n per 1000 person-
years
n per 1000 person-
years
n per 1000 person-
years
Death (all causes) 1 2.4 2 8.1 0 0 1 5.2
Non-fatal MI 0 0 1 4.1 0 0 0 0
Non-fatal stroke 1 2.4 0 0 1 5.8 1 5.2
Amputation 0 0 0 0 0 0 0 0
Hospitalisation AP 3 7.1 0 0 0 0 0 0
Hospitalisation CHF 0 0 0 0 0 0 1 5.2
Coronary 
revascularisation
0 0 28 . 115 . 80 0
Peripheral vascular 
events
2 4.8 3 12.2 1 5.8 0 0
Total 7 16.7 8 32.6 3 17.3 3 15.7*
* Differences between categories not significant.BMC Family Practice 2008, 9:67 http://www.biomedcentral.com/1471-2296/9/67
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ovascular risk factors. Moreover, our data demonstrated
that adequate control for cardiovascular risk factors in
asymptomatic diabetic patients identified by screening is
achievable in general practice. GPs might be relatively
unaware of the cardiovascular risk of screened persons
with impaired glucose regulation, they are not neglecting
the importance of treating screen-detected diabetic
patients. Our findings indicate that screening for an unfa-
vourable cardiovascular risk profile is preferable to screen-
ing for diabetes only.
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